Author

Dmitry G. Sherstnev

Observed names: D. G. Sherstnev, D. Sherstnev, Dmitrij G. Sherstnev, Dmitrij Sherstnev, Dmitry Sherstnev

Institution: Saratov State Medical University

Observed institution: Saratov State Medical University

ORCID: 0000-0002-2290-5180

Observed ORCID: 0000-0002-2290-5180

OpenAlex ID: A5079649774

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia

2022 · Olga Goronkova, Galina Novichkova, et al. · Blood Advances · 46

Bleeding rate reduction in children with hemophilia A and inhibitors treated with emicizumab in the real-world clinical setting

2022 · P. А. Zharkov, K. A. Voronin, et al. · Pediatric Hematology/Oncology and Immunopathology · 7

Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study

2022 · Ekaterina S. Nesterova, Aleksandra F. Saydullaeva, et al. · Journal of Modern Oncology · 5

Quality of Life Changes in Patients with Chronic Immune Thrombocytopenia in the Process of Romiplostim Therapy, its Efficacy and Safety in the Real-World Setting: Results of a Multi-Center Observational Study

2023 · T. I. Ionova, O. Yu. Vinogradova, et al. · Clinical oncohematology · 3

Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy

2021 · Ekaterina S. Nesterova, Tatyana Yu. Klitochenko, et al. · Journal of Modern Oncology · 3

Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting

2019 · Tatyana Ionova, Boris Afanasiev, et al. · Blood · 3

Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study

2024 · Ekaterina S. Nesterova, Aleksandra F. Saydullaeva, et al. · Journal of Modern Oncology · 2

P1724: Quality of Life and Unmet Needs Among Ph-negative Myeloproliferative Neoplasm Patients: Results of the Nationwide Survey

2022 · T. Ionova, E. Andreevskaya, et al. · HemaSphere

Pb2308: Quality of Life and Clinical Outcomes in Adult Patients With Chronic Immune Thrombocytopenia (citp) During Treatment With Romiplostim in a Real-world Setting

2022 · T. Ionova, O. Vinogradova, et al. · HemaSphere

The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice

2022 · T. I. Ionova, A. A. Amdiev, et al. · Clinical oncohematology

Brentuximab Vedotin for Treatment in Patients With Relapsed/refractory Classical Hodgkin Lymphoma in a Real World Setting: Clinical Outcomes and Impact on Quality of Life

2021 · T. Ionova, M. Andrievskikh, et al. · Hematological Oncology

Works count: 11

Citation count: 69

H-index: 3

I10-index: 1